Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GETUG-12: Adjuvant Docetaxel and Estramustine in High-Risk Prostate Cancer
NCT00055731Phase 3Completed
- Sponsor
- Unicancer
- Start
- Nov 2002
- Primary completion
- Dec 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel and estramustine in prostate cancer (PCa) (2 arms), sponsored by Unicancer. Primary endpoints: Progression-free survival at 15 years, Prostate-specific antigen level at 3 months and 5 more. Started Nov 2002; status: completed.
02
Drugs
docetaxelestramustine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00055731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055731.